^
Association details:
| Biomarker: | STK11 mutation |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) + Imjudo (tremelimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LBA59 - Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)
Published date:
09/05/2022
Excerpt:
A trend for OS benefit with T+D+CT vs CT continued to be observed in non-squamous subgroups with mutations (m) in STK11 (Table), KEAP1 or KRAS (data will be presented)….The results of this exploratory analysis from POSEIDON, after mFU of ∼4 y, demonstrate the durable long-term OS benefit of adding a limited course of T to D and 4 cycles of CT. These data support the use of this regimen as a 1L treatment option for pts with mNSCLC, including harder-to-treat mutational subgroups such as STK11m, KEAP1m or KRASm.
Secondary therapy:
Chemotherapy
Trial ID:
Source:
Title:
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients
Excerpt:
...- Participants must have tumors with STK11 or KEAP1 or KRAS mutations....
Trial ID:
Source:
Title:
Somatic STK11/LKB1 mutations to confer resistance to immune checkpoint inhibitors as monotherapy or in combination in advanced NSCLC.
Published date:
05/16/2018
Excerpt:
CONTRADICTING EVIDENCE: In two independent trials evaluating D as monotherapy (CP1108/Atlantic), and in a D + T combination trial (D4190C00006), reduced ORR and shorter survival were observed in Non-SQ NSCLC pts harboring STK11 non-synonymous mutant tumors...In Non-SQ NSCLC, somatic STK11 mt may confer innate resistance to immune checkpoint inhibitors.
DOI:
10.1200/JCO.2018.36.15_suppl.3028
Trial ID:
